RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
5.0%−95.0 pts over 5 years
Operating margin
-867.9%+1267.8 pts over 5 years
Net margin
-863.4%+1332.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +26.9% | +23.3% | +79.9% | – | |
| Gross profit | -72.6% | – | -1.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 52.6% | -59.5% | |
| Return on assets | – | – | -44.1% | |
| Current ratio | – | 11.53 | 5.50 | |
| Debt to equity | – | -0.06 | 0.02 | |
| Net debt to EBITDA | – | 3.17× | 1.28× | |
| Interest coverage | – | -62.2× | -358.1× | |
| Capex to revenue | – | 147.2% | 8.7% | |
| Diluted shares | – | 22M | 447M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Recursion Pharmaceuticals generated $1.26B from operations and spent $108.98M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.26B
Used
$108.98M
Capital expenditure$108.98M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-863.4%
×Asset turnover0.05×
×Equity multiplier1.35×
=Return on equity, FY2025-59.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -863.4% | 0.05× | 1.35× | -59.5% |
| FY2024 | -788.0% | 0.06× | 1.40× | -61.9% |
| FY2023 | -736.0% | 0.07× | 1.43× | -69.1% |
| FY2022 | -601.0% | 0.06× | 1.27× | -46.6% |
| FY2021 | -1832.2% | 0.02× | 2.70× | -110.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$644.76M
- Cash generatingOperating cash flow above zero-$371.81M
- Return on assets improvedROA up on the prior year-70.9% → -44.5%
- Earnings backed by cashOperating cash flow above net income-$371.81M vs -$644.76M
- Less leverageLong-term debt to assets fell1.3% → 0.6%
- Better liquidityCurrent ratio rose3.81 → 5.50
- No dilutionShare count did not rise274M → 447M
- Gross margin improvedGross margin up on the prior year23.12% → 4.99%
- More efficientAsset turnover rose0.09 → 0.05